- Advancements in Novel Immunotherapeutics in The Oncology Battle
Mar 24, 2026 · newsfilecorp.com
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - March 24, 2026) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at advancements in novel immunotherapeutics, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications. Advancements in Novel Immunotherapeutics in The Oncology Battle To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/6292/289695_0e46dab6145c8910_001full.jpg Novel immunotherapeutics have transformed oncology, moving away from broad, non-specific treatments toward highly personalized strategies that harness the patient's immune system to precisely target cancer cells.
- ADVANCEMENTS IN NOVEL IMMUNOTHERAPEUTICS IN THE ONCOLOGY BATTLE
Mar 24, 2026
VANCOUVER, KELOWNA, AND DELTA, BRITISH COLUMBIA--(NEWSFILE CORP. - MARCH 24, 2026) - INVESTORIDEAS.COM, A GO-TO INVESTING PLATFORM, RELEASES AN INDUSTRY SNAPSHOT LOOKING AT ADVANCEMENTS IN NOVEL IMMUNOTHERAPEUTICS, FEATURING AETHLON MEDICAL, INC. (NASDAQ: AEMD), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING THE INVESTIGATIONAL AETHLON HEMOPURIFIER®, AN EXTRACORPOREAL DEVICE FOR ONCOLOGY AND OTHER INDICATIONS. ADVANCEMENTS IN NOVEL IMMUNOTHERAPEUTICS IN THE ONCOLOGY BATTLE TO VIEW AN ENHANCED VERSION OF THIS GRAPHIC, PLEASE VISIT: HTTPS://IMAGES.NEWSFILECORP.COM/FILES/6292/289695_0E46DAB6145C8910_001FULL.JPG NOVEL IMMUNOTHERAPEUTICS HAVE TRANSFORMED ONCOLOGY, MOVING AWAY FROM BROAD, NON-SPECIFIC TREATMENTS TOWARD HIGHLY PERSONALIZED STRATEGIES THAT HARNESS THE PATIENT'S IMMUNE SYSTEM TO PRECISELY TARGET CANCER CELLS.
- Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review
Mar 24, 2026 · prnewswire.com
SAN DIEGO, March 24, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of the second cohort participant data and recommended advancing to the third and final cohort. They also stated that "no safety concerns were noted with Hemopurifier device/procedure".
- AETHLON MEDICAL, INC. ADVANCES TO FINAL COHORT IN ONCOLOGY CLINICAL TRIAL FOLLOWING POSITIVE DSMB REVIEW
Mar 24, 2026
SAN DIEGO, MARCH 24, 2026 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. (NASDAQ: AEMD), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING THE INVESTIGATIONAL AETHLON HEMOPURIFIER®, AN EXTRACORPOREAL DEVICE FOR ONCOLOGY AND OTHER INDICATIONS, TODAY ANNOUNCED THAT THE INDEPENDENT DATA SAFETY MONITORING BOARD (DSMB) OVERSEEING ITS ONGOING CLINICAL TRIAL AEMD-2022-06 HAS COMPLETED ITS SCHEDULED SAFETY REVIEW OF THE SECOND COHORT PARTICIPANT DATA AND RECOMMENDED ADVANCING TO THE THIRD AND FINAL COHORT. THEY ALSO STATED THAT "NO SAFETY CONCERNS WERE NOTED WITH HEMOPURIFIER DEVICE/PROCEDURE".
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Mar 13, 2026
Virtual Investor Conferences
NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing.
The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry.
REGISTER AND VIEW PRESENTATIONS HERE
The presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section.
Select companies are accepting 1x1 management meeting requests through March 17th.
Please Schedule 1x1 Meetings here
March 11th & 12th Presentation Ticker(s) SeaStar Medical Holding Corporation (NASDAQ: ICU) Nasus Pharma Ltd. (NYSE: NSRX) Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Jupiter Neurosciences, Inc. (NASDAQ: JUNS) Bora Pharmaceuticals Co., Ltd. (OTCQX: BORAY | TWSE: 6472) MetaVia Inc. (NASDAQ: MTVA) Phio Pharmaceuticals Corp. (NASDAQ: PHIO) Avicanna Inc. (OTCQX: AVCNF | TSX: AVCN) EMVision Medical Devices Ltd. (OTC: EMVDF | ASX: EMV) Aethlon Medical, Inc. (NASDAQ: AEMD) Dyadic International, Inc. (NASDAQ: DYAI) Jaguar Health, Inc. (NASDAQ: JAGX) Beyond Air, Inc. (NASDAQ: XAIR) Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) Amplia Therapeutics Ltd. (OTCQB: INNMF | ASX: ATX)
To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
Media Contact:
OTC Markets Group Inc. +1 (212) 896-4428, media@otcmarkets.com
Story Continues
Virtual Investor Conferences Contact:
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com
View Comments
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Mar 13, 2026
NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing.
The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry.
REGISTER AND VIEW PRESENTATIONS HERE
The presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section.
Select companies are accepting 1x1 management meeting requests through March 17th.
Please Schedule 1x1 Meetings here
March 11th & 12th PresentationTicker(s)SeaStar Medical Holding Corporation(NASDAQ: ICU)Nasus Pharma Ltd.(NYSE: NSRX)Tonix Pharmaceuticals Holding Corp.(NASDAQ: TNXP)Jupiter Neurosciences, Inc.(NASDAQ: JUNS)Bora Pharmaceuticals Co., Ltd.(OTCQX: BORAY | TWSE: 6472)MetaVia Inc.(NASDAQ: MTVA)Phio Pharmaceuticals Corp.(NASDAQ: PHIO)Avicanna Inc.(OTCQX: AVCNF | TSX: AVCN)EMVision Medical Devices Ltd.(OTC: EMVDF | ASX: EMV)Aethlon Medical, Inc.(NASDAQ: AEMD)Dyadic International, Inc.(NASDAQ: DYAI)Jaguar Health, Inc.(NASDAQ: JAGX)Beyond Air, Inc.(NASDAQ: XAIR) Cadrenal Therapeutics, Inc.(NASDAQ: CVKD)Amplia Therapeutics Ltd.(OTCQB: INNMF | ASX: ATX)
To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
Media Contact:
OTC Markets Group Inc. +1 (212) 896-4428, media@otcmarkets.com
Virtual Investor Conferences Contact:
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com
- Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities
Mar 12, 2026 · prnewswire.com
SAN DIEGO, March 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC ("Maxim") to act as the Company's exclusive financial advisor in connection with this process. The Company engaged Maxim following preliminary inbound interest regarding potential strategic opportunities.
- AETHLON MEDICAL ENGAGES MAXIM GROUP LLC TO EVALUATE STRATEGIC OPPORTUNITIES
Mar 12, 2026
SAN DIEGO, MARCH 12, 2026 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. ("AETHLON" OR THE "COMPANY") (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE-THREATENING INFECTIOUS DISEASES, TODAY ANNOUNCED THAT IT IS EVALUATING A RANGE OF STRATEGIC OPPORTUNITIES AND HAS ENGAGED MAXIM GROUP LLC ("MAXIM") TO ACT AS THE COMPANY'S EXCLUSIVE FINANCIAL ADVISOR IN CONNECTION WITH THIS PROCESS. THE COMPANY ENGAGED MAXIM FOLLOWING PRELIMINARY INBOUND INTEREST REGARDING POTENTIAL STRATEGIC OPPORTUNITIES.
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
Mar 10, 2026
Virtual Investor Conferences
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026.
Individual investors, institutional investors, advisors, and analysts are invited to attend.
REGISTER HERE
Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams.
Schedule 1x1 meetings here
“We are delighted to highlight today’s innovators from the Life Science sector,” said Jason Paltrowitz, EVP of Corporate Services at OTC Markets Group. “Our Virtual Investor Conferences continue to provide an efficient platform and unique opportunity for these companies to engage to a broader investor base and communicate their strategies.”
March 11th
Eastern
Time (ET) Presentation Ticker(s) 12:00 PM SeaStar Medical Holding Corporation (NASDAQ: ICU) 12:30 PM Nasus Pharma Ltd. (NYSE: NSRX) 1:00 PM Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) 1:30 PM Jupiter Neurosciences, Inc. (NASDAQ: JUNS)
March 12th
Eastern
Time (ET) Presentation Ticker(s) 09:30 AM Bora Pharmaceuticals Co., Ltd. (OTCQX: BORAY | TWSE: 6472) 10:00 AM Prostatype Genomics AB (OTCQB: PGABF | NASDAQ Stockholm: PROGEN) 10:30 AM MetaVia Inc. (NASDAQ: MTVA) 11:00 AM Phio Pharmaceuticals Corp. (NASDAQ: PHIO) 11:30 AM Avicanna Inc. (OTCQX: AVCNF | TSX: AVCN) 12:00 PM EMVision Medical Devices Ltd. (OTC: EMVDF | ASX: EMV) 1:00 PM Aethlon Medical, Inc. (NASDAQ: AEMD) 1:30 PM Dyadic International, Inc. (NASDAQ: DYAI) 2:00 PM Jaguar Health, Inc. (NASDAQ: JAGX) 2:30 PM Beyond Air, Inc. (NASDAQ: XAIR) 3:00 PM Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) 3:30 PM Amplia Therapeutics Ltd. (OTCQB: INNMF | ASX: ATX)
To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
Story Continues
Media Contact:
OTC Markets Group Inc. +1 (212) 896-4428, media@otcmarkets.com
Virtual Investor Conferences Contact:
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com
View Comments
- Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th
Mar 6, 2026 · globenewswire.com
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com